244 related articles for article (PubMed ID: 30083962)
1. Phase II randomized, double-blind, placebo-controlled study of tivantinib in men with asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer (mCRPC).
Monk P; Liu G; Stadler WM; Geyer S; Huang Y; Wright J; Villalona-Calero M; Wade J; Szmulewitz R; Gupta S; Mortazavi A; Dreicer R; Pili R; Dawson N; George S; Garcia JA
Invest New Drugs; 2018 Oct; 36(5):919-926. PubMed ID: 30083962
[TBL] [Abstract][Full Text] [Related]
2. A randomized, double-blind, placebo-controlled, phase III trial of erlotinib with or without a c-Met inhibitor tivantinib (ARQ 197) in Asian patients with previously treated stage IIIB/IV nonsquamous nonsmall-cell lung cancer harboring wild-type epidermal growth factor receptor (ATTENTION study).
Yoshioka H; Azuma K; Yamamoto N; Takahashi T; Nishio M; Katakami N; Ahn MJ; Hirashima T; Maemondo M; Kim SW; Kurosaki M; Akinaga S; Park K; Tsai CM; Tamura T; Mitsudomi T; Nakagawa K
Ann Oncol; 2015 Oct; 26(10):2066-72. PubMed ID: 26153496
[TBL] [Abstract][Full Text] [Related]
3. A phase I study of tivantinib in combination with temsirolimus in patients with advanced solid tumors.
Kyriakopoulos CE; Braden AM; Kolesar JM; Eickhoff JC; Bailey HH; Heideman J; Liu G; Wisinski KB
Invest New Drugs; 2017 Jun; 35(3):290-297. PubMed ID: 28004284
[TBL] [Abstract][Full Text] [Related]
4. Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study.
Rimassa L; Assenat E; Peck-Radosavljevic M; Pracht M; Zagonel V; Mathurin P; Rota Caremoli E; Porta C; Daniele B; Bolondi L; Mazzaferro V; Harris W; Damjanov N; Pastorelli D; Reig M; Knox J; Negri F; Trojan J; López López C; Personeni N; Decaens T; Dupuy M; Sieghart W; Abbadessa G; Schwartz B; Lamar M; Goldberg T; Shuster D; Santoro A; Bruix J
Lancet Oncol; 2018 May; 19(5):682-693. PubMed ID: 29625879
[TBL] [Abstract][Full Text] [Related]
5. Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study.
Santoro A; Rimassa L; Borbath I; Daniele B; Salvagni S; Van Laethem JL; Van Vlierberghe H; Trojan J; Kolligs FT; Weiss A; Miles S; Gasbarrini A; Lencioni M; Cicalese L; Sherman M; Gridelli C; Buggisch P; Gerken G; Schmid RM; Boni C; Personeni N; Hassoun Z; Abbadessa G; Schwartz B; Von Roemeling R; Lamar ME; Chen Y; Porta C
Lancet Oncol; 2013 Jan; 14(1):55-63. PubMed ID: 23182627
[TBL] [Abstract][Full Text] [Related]
6. Phase II study of tivantinib (ARQ 197) in patients with metastatic triple-negative breast cancer.
Tolaney SM; Tan S; Guo H; Barry W; Van Allen E; Wagle N; Brock J; Larrabee K; Paweletz C; Ivanova E; Janne P; Overmoyer B; Wright JJ; Shapiro GI; Winer EP; Krop IE
Invest New Drugs; 2015 Oct; 33(5):1108-14. PubMed ID: 26123926
[TBL] [Abstract][Full Text] [Related]
7. Selective Inhibitor of the c-Met Receptor Tyrosine Kinase in Advanced Hepatocellular Carcinoma: No Beneficial Effect With the Use of Tivantinib?
Zhao S; Wu W; Jiang H; Ma L; Pan C; Jin C; Mo J; Wang L; Wang K
Front Immunol; 2021; 12():731527. PubMed ID: 34804015
[TBL] [Abstract][Full Text] [Related]
8. A Phase II Study of the c-Met Inhibitor Tivantinib in Combination with FOLFOX for the Treatment of Patients with Previously Untreated Metastatic Adenocarcinoma of the Distal Esophagus, Gastroesophageal Junction, or Stomach.
Pant S; Patel M; Kurkjian C; Hemphill B; Flores M; Thompson D; Bendell J
Cancer Invest; 2017 Aug; 35(7):463-472. PubMed ID: 28662341
[TBL] [Abstract][Full Text] [Related]
9. A phase II trial of a selective c-Met inhibitor tivantinib (ARQ 197) monotherapy as a second- or third-line therapy in the patients with metastatic gastric cancer.
Kang YK; Muro K; Ryu MH; Yasui H; Nishina T; Ryoo BY; Kamiya Y; Akinaga S; Boku N
Invest New Drugs; 2014 Apr; 32(2):355-61. PubMed ID: 24337769
[TBL] [Abstract][Full Text] [Related]
10. Tivantinib in hepatocellular carcinoma.
Trojan J; Zeuzem S
Expert Opin Investig Drugs; 2013 Jan; 22(1):141-7. PubMed ID: 23167786
[TBL] [Abstract][Full Text] [Related]
11. Rationale and design of MARQUEE: a phase III, randomized, double-blind study of tivantinib plus erlotinib versus placebo plus erlotinib in previously treated patients with locally advanced or metastatic, nonsquamous, non-small-cell lung cancer.
Scagliotti GV; Novello S; Schiller JH; Hirsh V; Sequist LV; Soria JC; von Pawel J; Schwartz B; Von Roemeling R; Sandler AB
Clin Lung Cancer; 2012 Sep; 13(5):391-5. PubMed ID: 22440336
[TBL] [Abstract][Full Text] [Related]
12. Phase II Study of Tivantinib and Cetuximab in Patients With KRAS Wild-type Metastatic Colorectal Cancer With Acquired Resistance to EGFR Inhibitors and Emergence of MET Overexpression: Lesson Learned for Future Trials With EGFR/MET Dual Inhibition.
Rimassa L; Bozzarelli S; Pietrantonio F; Cordio S; Lonardi S; Toppo L; Zaniboni A; Bordonaro R; Di Bartolomeo M; Tomasello G; Dadduzio V; Tronconi MC; Piombo C; Giordano L; Gloghini A; Di Tommaso L; Santoro A
Clin Colorectal Cancer; 2019 Jun; 18(2):125-132.e2. PubMed ID: 30846365
[TBL] [Abstract][Full Text] [Related]
13. A phase I dose-escalation study of Tivantinib (ARQ 197) in adult patients with metastatic solid tumors.
Rosen LS; Senzer N; Mekhail T; Ganapathi R; Chai F; Savage RE; Waghorne C; Abbadessa G; Schwartz B; Dreicer R
Clin Cancer Res; 2011 Dec; 17(24):7754-64. PubMed ID: 21976535
[TBL] [Abstract][Full Text] [Related]
14. A randomized, double-blind, placebo-controlled, phase 3 study of tivantinib in Japanese patients with MET-high hepatocellular carcinoma.
Kudo M; Morimoto M; Moriguchi M; Izumi N; Takayama T; Yoshiji H; Hino K; Oikawa T; Chiba T; Motomura K; Kato J; Yasuchika K; Ido A; Sato T; Nakashima D; Ueshima K; Ikeda M; Okusaka T; Tamura K; Furuse J
Cancer Sci; 2020 Oct; 111(10):3759-3769. PubMed ID: 32716114
[TBL] [Abstract][Full Text] [Related]
15. Tivantinib (ARQ197) in hepatocellular carcinoma.
Porta C; Giglione P; Ferrari A; Reversi F; Liguigli W; Imarisio I; Ganini C
Expert Rev Anticancer Ther; 2015 Jun; 15(6):615-22. PubMed ID: 26035719
[TBL] [Abstract][Full Text] [Related]
16. Randomized, Double-Blind, Phase III Trial of Ipilimumab Versus Placebo in Asymptomatic or Minimally Symptomatic Patients With Metastatic Chemotherapy-Naive Castration-Resistant Prostate Cancer.
Beer TM; Kwon ED; Drake CG; Fizazi K; Logothetis C; Gravis G; Ganju V; Polikoff J; Saad F; Humanski P; Piulats JM; Gonzalez Mella P; Ng SS; Jaeger D; Parnis FX; Franke FA; Puente J; Carvajal R; Sengeløv L; McHenry MB; Varma A; van den Eertwegh AJ; Gerritsen W
J Clin Oncol; 2017 Jan; 35(1):40-47. PubMed ID: 28034081
[TBL] [Abstract][Full Text] [Related]
17. A randomized, placebo-controlled, phase 1/2 study of tivantinib (ARQ 197) in combination with irinotecan and cetuximab in patients with metastatic colorectal cancer with wild-type KRAS who have received first-line systemic therapy.
Eng C; Bessudo A; Hart LL; Severtsev A; Gladkov O; Müller L; Kopp MV; Vladimirov V; Langdon R; Kotiv B; Barni S; Hsu C; Bolotin E; von Roemeling R; Schwartz B; Bendell JC
Int J Cancer; 2016 Jul; 139(1):177-86. PubMed ID: 26891420
[TBL] [Abstract][Full Text] [Related]
18. Phase II study of the c-MET inhibitor tivantinib (ARQ 197) in patients with relapsed or relapsed/refractory multiple myeloma.
Baljevic M; Zaman S; Baladandayuthapani V; Lin YH; de Partovi CM; Berkova Z; Amini B; Thomas SK; Shah JJ; Weber DM; Fu M; Cleeland CS; Wang XS; Stellrecht CM; Davis RE; Gandhi V; Orlowski RZ
Ann Hematol; 2017 Jun; 96(6):977-985. PubMed ID: 28337527
[TBL] [Abstract][Full Text] [Related]
19. Randomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancer.
Sequist LV; von Pawel J; Garmey EG; Akerley WL; Brugger W; Ferrari D; Chen Y; Costa DB; Gerber DE; Orlov S; Ramlau R; Arthur S; Gorbachevsky I; Schwartz B; Schiller JH
J Clin Oncol; 2011 Aug; 29(24):3307-15. PubMed ID: 21768463
[TBL] [Abstract][Full Text] [Related]
20. A phase 2 multicenter study of tivantinib (ARQ 197) monotherapy in patients with relapsed or refractory germ cell tumors.
Feldman DR; Einhorn LH; Quinn DI; Loriot Y; Joffe JK; Vaughn DJ; Fléchon A; Hajdenberg J; Halim AB; Zahir H; Motzer RJ
Invest New Drugs; 2013 Aug; 31(4):1016-22. PubMed ID: 23417696
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
